Metformin-Associated Lactic Acidosis in Clinical Diabetes Management

Metformin is the cornerstone of first-line therapy for type 2 diabetes mellitus owing to its proven efficacy in lowering blood glucose, favourable cardiovascular profile and cost-effectiveness. In rare circumstances, accumulation of metformin can precipitate severe lactic acidosis, a life-threatening metabolic disturbance characterised by an elevated blood lactate concentration and acidemia. The risk is heightened in the presence of renal impairment, hypovolaemia, hepatic dysfunction or conditions causing tissue hypoxia. Pathophysiologically, metformin inhibits mitochondrial complex I, reducing oxidative phosphorylation and shifting metabolism towards anaerobic glycolysis with lactate overproduction. Clinically, patients present with malaise, abdominal pain, tachypnoea and altered mental status. Management centres on immediate cessation of metformin, correction of acid–base and electrolyte disturbances, circulatory support and, when indicated, renal replacement therapies to remove metformin and lactate and to restore acid–base balance. Despite historical mortality rates approaching 50 per cent in severe cases, early recognition and prompt initiation of extracorporeal treatment have substantially improved outcomes. Ongoing research seeks to refine risk stratification, optimise renal support modalities and confirm safety thresholds for metformin use in patients with fluctuating renal function.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Metformin-Associated Lactic Acidosis in Clinical Diabetes Management publication trend

The graph below shows the total number of articles in metformin-associated lactic acidosis in clinical diabetes management across all publications each year (not limited to Nature Index journals).

Technical terms

Metformin-Associated Lactic Acidosis (MALA): A rare but serious condition in which metformin accumulation leads to elevated lactate production and acidemia.

Acute Kidney Injury (AKI): A sudden decline in renal function that impairs drug clearance and predisposes to metabolic disturbances.

Haemodialysis: An extracorporeal therapy that removes toxins and corrects acid–base imbalances by filtering blood through a semipermeable membrane.

Euglycaemic Ketoacidosis: A metabolic state characterised by ketoacid accumulation despite normal blood glucose, sometimes occurring alongside MALA in patients with compromised gluconeogenesis.

References

1. Risk of Lactic Acidosis in Hospitalized Diabetic Patients Prescribed Biguanides in Japan: A Retrospective Total-Population Cohort Study. International Journal of Environmental Research and Public Health (2023).
2. Serum lactate level and mortality in metformin-associated lactic acidosis requiring renal replacement therapy: a systematic review of case reports and case series. BMC Nephrology (2017).
3. Metformin associated lactic acidosis: a case series of 28 patients treated with sustained low-efficiency dialysis (SLED) and long-term follow-up. BMC Nephrology (2018).